The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5

INTRODUCTION: Lenalidomide is an active agent that was approved for use in the EU in 2015 as a first-line therapy for previously untreated, non-transplant eligible multiple myeloma patients. Our objective was to assess the cost impact of lenalidomide when selected as a first-line treatment for trans...

Descripción completa

Detalles Bibliográficos
Autores principales: Schey, Steve, Montero, Luis Felipe Casado, Stengel-Tosetti, Chloe, Gibson, Craig J., Dhanasiri, Sujith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488111/
https://www.ncbi.nlm.nih.gov/pubmed/28680953
http://dx.doi.org/10.1007/s40487-016-0037-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488111/
https://www.ncbi.nlm.nih.gov/pubmed/28680953
http://dx.doi.org/10.1007/s40487-016-0037-8

Ejemplares similares